211 related articles for article (PubMed ID: 36728601)
1. Molecular landscape of myelodysplastic neoplasms in disease classification and prognostication.
Maggioni G; Della Porta MG
Curr Opin Hematol; 2023 Mar; 30(2):30-37. PubMed ID: 36728601
[TBL] [Abstract][Full Text] [Related]
2. The clinical, molecular, and prognostic features of the 2022 WHO and ICC classification systems for myelodysplastic neoplasms.
Khanna V; Lu R; Kumar J; Molina A; Stehr H; Spiteri E; Spinner M; Silva O; Fernandez-Pol S; Tan B; Greenberg PL
Leuk Res; 2024 Jan; 136():107433. PubMed ID: 38154193
[TBL] [Abstract][Full Text] [Related]
3. The International Consensus Classification of myelodysplastic syndromes and related entities.
Hasserjian RP; Orazi A; Orfao A; Rozman M; Wang SA
Virchows Arch; 2023 Jan; 482(1):39-51. PubMed ID: 36287260
[TBL] [Abstract][Full Text] [Related]
4. Clinico-genetic and prognostic analyses of 716 patients with primary myelodysplastic syndrome and myelodysplastic syndrome/acute myeloid leukemia based on the 2022 International Consensus Classification.
Lee WH; Lin CC; Tsai CH; Tien FM; Lo MY; Ni SC; Yao M; Tseng MH; Kuo YY; Liu MC; Tang JL; Sun HI; Chuang YK; Chou WC; Hou HA; Tien HF
Am J Hematol; 2023 Mar; 98(3):398-407. PubMed ID: 36588411
[TBL] [Abstract][Full Text] [Related]
5. Pathologic Spectrum and Molecular Landscape of Myeloid Disorders Harboring SF3B1 Mutations.
Venable ER; Chen D; Chen CP; Bessonen KR; Nguyen PL; Oliveira JL; Reichard KK; Hoyer JD; Althoff SD; Roh DJ; Miller MA; Begna K; Patnaik MM; Litzow MR; Al-Kali A; Viswanatha DS; He R
Am J Clin Pathol; 2021 Sep; 156(4):679-690. PubMed ID: 33978189
[TBL] [Abstract][Full Text] [Related]
6. How to classify risk based on clinical and molecular modeling: integrating molecular markers in the risk assessment of myelodysplastic syndrome.
Xian RR
Hematology Am Soc Hematol Educ Program; 2023 Dec; 2023(1):51-58. PubMed ID: 38066895
[TBL] [Abstract][Full Text] [Related]
7. Risk stratifying MDS in the time of precision medicine.
Cazzola M
Hematology Am Soc Hematol Educ Program; 2022 Dec; 2022(1):375-381. PubMed ID: 36485160
[TBL] [Abstract][Full Text] [Related]
8. Implications of the 5
Lee C; Kim HN; Kwon JA; Yoon SY; Jeon MJ; Yu ES; Kim DS; Choi CW; Yoon J
Ann Lab Med; 2023 Sep; 43(5):503-507. PubMed ID: 37080752
[TBL] [Abstract][Full Text] [Related]
9. The International Consensus Classification of acute myeloid leukemia.
Weinberg OK; Porwit A; Orazi A; Hasserjian RP; Foucar K; Duncavage EJ; Arber DA
Virchows Arch; 2023 Jan; 482(1):27-37. PubMed ID: 36264379
[TBL] [Abstract][Full Text] [Related]
10. Diagnosis and Classification of Myelodysplastic Syndromes with Mutated TP53.
Siddon AJ; Weinberg OK
Clin Lab Med; 2023 Dec; 43(4):607-614. PubMed ID: 37865506
[TBL] [Abstract][Full Text] [Related]
11. Understanding the Continuum between High-Risk Myelodysplastic Syndrome and Acute Myeloid Leukemia.
Zavras PD; Sinanidis I; Tsakiroglou P; Karantanos T
Int J Mol Sci; 2023 Mar; 24(5):. PubMed ID: 36902450
[TBL] [Abstract][Full Text] [Related]
12. Recurrent Cytogenetic Abnormalities in Myelodysplastic Syndromes.
Wall M
Methods Mol Biol; 2017; 1541():209-222. PubMed ID: 27910026
[TBL] [Abstract][Full Text] [Related]
13. Trisomy 11 in myelodysplastic syndromes defines a unique group of disease with aggressive clinicopathologic features.
Wang SA; Jabbar K; Lu G; Chen SS; Galili N; Vega F; Jones D; Raza A; Kantarjian H; Garcia-Manero G; McDonnell TJ; Medeiros LJ
Leukemia; 2010 Apr; 24(4):740-7. PubMed ID: 20072149
[TBL] [Abstract][Full Text] [Related]
14. Enumerating bone marrow blasts from nonerythroid cellularity improves outcome prediction in myelodysplastic syndromes and permits a better definition of the intermediate risk category of the Revised International Prognostic Scoring System (IPSS-R).
Calvo X; Arenillas L; Luño E; Senent L; Arnan M; Ramos F; Pedro C; Tormo M; Montoro J; Díez-Campelo M; Blanco ML; Arrizabalaga B; Xicoy B; Bonanad S; Jerez A; Nomdedeu M; Ferrer A; Sanz GF; Florensa L
Am J Hematol; 2017 Jul; 92(7):614-621. PubMed ID: 28370234
[TBL] [Abstract][Full Text] [Related]
15. Molecular Drivers of Myelodysplastic Neoplasms (MDS)-Classification and Prognostic Relevance.
Hoff FW; Madanat YF
Cells; 2023 Feb; 12(4):. PubMed ID: 36831294
[TBL] [Abstract][Full Text] [Related]
16. Clinical significance of SF3B1 mutations in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms.
Malcovati L; Papaemmanuil E; Bowen DT; Boultwood J; Della Porta MG; Pascutto C; Travaglino E; Groves MJ; Godfrey AL; Ambaglio I; Gallì A; Da Vià MC; Conte S; Tauro S; Keenan N; Hyslop A; Hinton J; Mudie LJ; Wainscoat JS; Futreal PA; Stratton MR; Campbell PJ; Hellström-Lindberg E; Cazzola M;
Blood; 2011 Dec; 118(24):6239-46. PubMed ID: 21998214
[TBL] [Abstract][Full Text] [Related]
17. Genetic Testing in Acute Myeloid Leukemia and Myelodysplastic Syndromes.
Nardi V; Hasserjian RP
Surg Pathol Clin; 2016 Mar; 9(1):143-63. PubMed ID: 26940274
[TBL] [Abstract][Full Text] [Related]
18. Validation of the molecular international prognostic scoring system in patients with myelodysplastic syndromes defined by international consensus classification.
Lee WH; Tsai MT; Tsai CH; Tien FM; Lo MY; Tseng MH; Kuo YY; Liu MC; Yang YT; Chen JC; Tang JL; Sun HI; Chuang YK; Lin LI; Chou WC; Lin CC; Hou HA; Tien HF
Blood Cancer J; 2023 Aug; 13(1):120. PubMed ID: 37558665
[TBL] [Abstract][Full Text] [Related]
19. Recent Clinical and Molecular Advances for the Classification of Myelodysplastic Neoplasms.
DeZern AE; Greenberg PL
J Natl Compr Canc Netw; 2022 Dec; 20(12):1280-1283. PubMed ID: 36509078
[TBL] [Abstract][Full Text] [Related]
20. Molecular characterization and prognosis of mutant TP53 acute myeloid leukemia and myelodysplastic syndrome with excess blasts.
Shen K; Hu DY; Zhang ZB; Guo YS; Zhang FH; Chen SN
Int J Lab Hematol; 2023 Jun; 45(3):344-352. PubMed ID: 36860196
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
